Rda Financial Network Gilead Sciences, Inc. Transaction History

Rda Financial Network

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 13, 2023	BUY	$76.01 - $86.7 $57,843 - $65,978	761 Added 17.19%	5,189 $399,000
Q1 2023 Apr 12, 2023	BUY	$77.31 - $88.08 $42,520 - $48,444	550 Added 14.18%	4,428 $367,000
Q4 2022 Jan 10, 2023	BUY	$62.32 - $89.47 $241,676 - $346,964	3,878 New	3,878 $0
Q4 2020 Feb 05, 2021	SELL	$56.65 - $64.55 $188,757 - $215,080	-3,332 Closed	0 $0
Q3 2020 Oct 13, 2020	BUY	$62.1 - $78.08 $2,794 - $3,513	45 Added 1.37%	3,332 $211,000
Q2 2020 Jul 14, 2020	SELL	$72.34 - $84.0 $61,778 - $71,736	-854 Reduced 20.62%	3,287 $253,000
Q1 2020 Apr 06, 2020	SELL	$62.63 - $80.22 $457,261 - $585,686	-7,301 Reduced 63.81%	4,141 $310,000
Q4 2019 Jan 30, 2020	SELL	$61.62 - $67.78 $55,149 - $60,663	-895 Reduced 7.25%	11,442 $736,000
Q3 2019 Nov 20, 2019	BUY	$62.51 - $69.0 $6,313 - $6,969	101 Added 0.83%	12,337 $802,000
Q2 2019 Jul 09, 2019	BUY	$61.87 - $69.38 $9,033 - $10,129	146 Added 1.21%	12,236 $826,000
Q1 2019 Apr 30, 2019	BUY	$62.53 - $70.05 $755,987 - $846,904	12,090 New	12,090 $791,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Rda Financial Network, based on Form 13F filings with the SEC.

Stay updated on Rda Financial Network with notifications on news.